Resources

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million.

The Milner Therapeutics Institute is delighted to be featured in a new report celebrating a decade of partnership and impact between AstraZeneca and the University of Cambridge.

Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry, has appointed Dr Ed Samuel as its Chief Operations Officer (COO).

Pioneer Group and Science Creates today announce a new partnership that will support the next generation of science and technology ventures across the UK and Ireland.

Logical Biological, biospecimen and critical material experts, today announced the launch of a new sister company, Logical Antigen, focused on rapid and customised delivery of high-quality antigens and biologicals, for research and manufacturing of diagnostic products.

PIR International recently partnered with Sibylla Biotech in appointing Dieter Weinand as Non-Executive Chair.

A response from Discovery Park’s CEO, Mayer Schreiber, in light of the Government’s Life Science Sector Plan.

Myricx Bio announces that it has been awarded the Cancer Research Horizons Start-Up Achievement Recognition Award for 2025, which it received at a ceremony in London last night.

Cellular Origins, the Cell and Gene Therapy Catapult and Resolution Therapeutics today announce the formation of a consortium which has been awarded a cross-industry Smart Grant of £1 million from Innovate UK, the UK’s national innovation agency.

Coulter Partners successfully completed a search assignment for QBiotics Group Limited (QBiotics) and announces the placement of Sergio Duchini as Non-executive Director.

PIR International spoke with the Chief Executive Officer of Muna Therapeutics, Rita Balice-Gordon, as part of their BioLeader interview series.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced the winners of its third Innovation and Entrepreneurship Awards.

The BioIndustry Association (BIA) today announces that Canary Wharf Group (CWG) and Kadans Science Partner (Kadans) have joined as annual supporters. This is a move that speaks to the strength of BIA and the vitality of the UK life sciences ecosystem.

Today, the British Business Bank has announced a new £400 million Investor Pathways Capital initiative, which will support diverse and emerging fund managers across the economy and make it easier for new entrants, particularly those from underrepresented groups, to break into venture capital.

Coulter Partners successfully completed a search assignment for Biomia and is pleased to announce the placement of Frederick Westhorpe, PhD as Chief Scientific Officer (CSO).

Coulter Partners successfully completed search assignments for Augustine Therapeutics NV.

Hosted at West Road Concert Hall in Cambridge, the Symposium brings together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics.

Their vanguard, breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics.

Rinri Therapeutics is focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, providing new therapeutic options for the treatment of this major global unmet medical need.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed its first Clinical Advisory Board to provide strategic guidance on the development of novel cancer therapeutics emerging from its drug discovery division, Therapeutic Innovation.